Montero-Menárguez, J.Amat Samaranch, V.Puig Sanz, L.Ruiz-Villaverde, R.Arias-Santiago, S.Larrea García, M.Ruiz Genao, D.Ferrán, M.Schneller-Pavelescu, L.Romero Ferreiro, C.Rivera Díaz, R.2026-02-042026-02-042024-09Montero-Menárguez, J, Amat Samaranch, V, Puig Sanz, L, Ruiz-Villaverde, R, Arias-Santiago, S, Larrea García, M, Ruiz Genao, D, Ferrán, M, Schneller-Pavelescu, L, Romero Ferreiro, C & Rivera Díaz, R 2024, 'Pityriasis Rubra Pilaris : A Multicentric Case Series of 65 Spanish Patients', Actas Dermo-Sifiliograficas, vol. 115, no. 8, pp. 761-765. https://doi.org/10.1016/j.ad.2024.02.0190001-7310https://hdl.handle.net/10641/7814Publisher Copyright: © 2024 AEDVIntroduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians. Objective: To add our experience to increase evidence about PRP. Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP. Results: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response. Conclusion: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.5569687enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Biologic agentsErythrodermaPityriasis rubra pilarisPathology and Forensic MedicineHistologyDermatologyMulticenter StudyJournal ArticleYesyesjournal articleopen access10.1016/j.ad.2024.02.019https://www.scopus.com/pages/publications/85188699007https://www.scopus.com/pages/publications/85188699007#tab=citedBy